High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone

Andreas Mueller, Ralf Dittrich, Helge Binder, Werner Kuehnel1, Theodoros Maltaris, Inge Hoffmann and Matthias W Beckmann

Department of Obstetrics and Gynecology, Erlangen University Hospital, Universitaetsstrasse 21–23, D-91054 Erlangen, Germany and 1DPC Academy, D-61231 Bad Nauheim, Germany

(Correspondence should be addressed to A Mueller; Email: andreas.mueller@gyn.imed.uni-erlangen.de)

(A Mueller and R Dittrich contributed equally to this work)

Abstract

Objective: To study the effect of estrogen (E) on the male skeleton in the absence of testosterone (T).

Design: Retrospective analyses of 40 middle-aged transsexuals treated with subcutaneous injections of gonadotropin-releasing hormone agonist every 4 weeks and oral 17-beta-estradiol-valerate 6 mg/day over two years until reassignment surgery.

Methods: The bone mineral density (BMD) in the femoral neck and lumbar spine (L2–L4) was measured with dual-energy X-ray absorptiometry at the beginning of cross-sex hormone treatment, after 12 and 24 months, and serum T, E, sex hormone-binding globulin (SHBG), calcitonin (CAL), osteocalcin (OSC), and urinary free deoxypyridinoline (DPD) were measured.

Results: After 12 months, a significant increase in BMD in the lumbar spine from 1.2 to 1.234 g/cm² and after 24 months to 1.274 g/cm² was observed. There was a significant increase in BMD in the femoral neck area from 1.068 to 1.109 g/cm² after 24 months. There was a significant decrease in serum T levels from 18.65 to 0.57 nmol/l after 12 months, and to 0.62 nmol/l after 24 months, a significant increase in SHBG levels from 50.09 to 125 nmol/l after 12 months, and to 130 nmol/l after 24 months, and a significant increase in serum E levels from 73.42 to 881.6 pmol/l after 12 months, and to 923.62 pmol/l after 24 months of cross-sex hormone treatment. Serum levels of CAL, OSC and urinary DPD were unchanged.

Conclusion: We conclude that high dose E treatment is able to increase BMD significantly in the femoral neck and lumbar spine independently of serum T levels in middle-aged men. There is no risk of osteoporosis developing in male-to-female transsexuals receiving GnRHa when there is an adequate E substitution.

European Journal of Endocrinology 153 107–113

Introduction

The relevance of testosterone (T) in comparison with estrogen (E) in regulating bone turnover in men remains unclear, while the maintenance of E in regulating bone metabolism in women is well established. The traditional belief was that T is the major sex steroid regulating bone metabolism in men. In elderly men, however, a significant relationship has been found between E serum levels and bone mineral density (BMD) (1–3). In detail, E was shown to regulate bone resorption enhancing bone mass, while T together with E is responsible for bone formation in men (4). Some results, however, suggested that Es play a dominant role in regulating bone turnover in both men and women. Furthermore, in men homozygous mutations in the E receptor-alpha (ER-alpha) gene or homozygous mutations in the aromatase gene have been found to be associated with osteopenia, unfused epiphyses and elevated indices of bone turnover. In men with homozygous mutations in the aromatase gene, E treatment was able to reverse these circumstances successfully (5–8). In addition, in men aged 22–39 years, an increase in BMD correlated more with serum E levels than with T levels (9). All of this evidence suggests the consideration that E also plays a role in bone formation processes and in the acquisition of peak bone mass in men. The results of different studies have been contradictory, however. Villimäki et al. reported that E may suppress both bone formation and resorption in a
population of young Finnish men (10). Several observational studies have attempted to address this issue in elderly men who are affected by age-related loss of BMD, which is a function of both peak bone mass and bone loss with aging (1, 2, 11, 12). In general, studying the effect of E independently of T on bone metabolism in younger or middle-aged men is difficult, while suppression of T is undesired in men in general.

In transsexual people, cross-sex hormone therapy is an important component of medical treatment, especially to provide relief from the dichotomy between body habitus and gender identity (13). Endocrine treatment is guided by the development of the desired mental changes and by the onset and maintenance of an acceptable physical state of the opposite sex. Ideally, this should still be a speedy process. Standards of care for the medical management of transsexual people have been proposed by the Harry Benjamin International Gender Dysphoria Association, Inc. (14). For feminizing endocrine treatment in male-to-female transsexual people, the most widely used drugs are Es in doses two to three times higher than the recommended doses for hormone replacement therapy (HRT) in postmenopausal women. The most widely applied Es are ethinyl estradiol 50–100 µg/day, followed by conjugated equine estrogens 0.625 mg/day or 17-beta-estradiol-valerate 5 mg/day and transdermal or intramuscular estrogens. Oral delivery is preferred by most centers (15). To potentiate the effects of E treatment, hormonal modulators or antiandrogens are used in order to lower serum levels of testosterone or to block its receptor and to limit masculine secondary sexual characteristics. When E treatment alone is less effective in producing adequate feminization, cyproterone acetate 100 mg/day, spironolactone 100–200 mg/day or flutamide 750 mg/day are often used together with Es. A synergistic effect of Es on physical and emotional changes has been observed with these combinations (15, 16). With regard to bone metabolism and the risk of developing osteoporosis, only two studies have been published, including 10 and 20 male-to-female transsexuals, respectively, with an observation period of more than one year (17, 18). Antiandrogens were used in the reported treatment regimen to reduce T levels.

We prefer the administration of gonadotropin-releasing hormone agonist (GnRHa), to avoid possible side effects of cyproterone acetate, such as depression and idiosyncratic severe hepatotoxicity, and to reduce serum T levels significantly. GnRHa together with 17-beta-estradiol-valerate for endocrine treatment in male-to-female transsexual people is the combination we usually administer until sex reassignment surgery (SRS). In general, GnRHa treatment results in a severe hypogonadal state and is followed by a dramatic decline in endogenous T serum levels. Depletion of T production in combination with E supplementation results in a radical change in the hormonal environment in biological men. Male-to-female transsexuals are therefore appropriate for studying the role of Es as potential regulators of bone metabolism in men in the absence of T.

In the present study, we evaluated the effects of high dose E treatment on bone metabolism in middle-aged male-to-female transsexuals with complete androgen deprivation. The aim was to assess whether Es are able to prevent GnRHa-induced bone loss and may be able to increase BMD in middle-aged men, at which time the peak bone mass has already been achieved (19).

**Materials and methods**

**Patient population**

The study population comprised 40 healthy middle-aged male-to-female transsexual people; their mean age was 38.4 years (S.D. 11.09) and the median body mass index (BMI) was 24.02 kg/m² (S.D. 4.00). The diagnosis of transsexualism followed the specifications of the Standards of Care of the Harry Benjamin Gender Dysphoria Association (14). The study was approved by the Ethics Committee of the Department of Medicine at Erlangen University Hospital, and informed consent was obtained from all of the patients. In our hospital, sex reassignment treatment implies 24 months of cross-sex hormone treatment (i.e. GnRHa and 17-beta-estradiol-valerate for males) before sex-reassignment surgery with gonadectomy, after which cross-sex hormone treatment has to be continued. All of the patients were interviewed regarding their medical history, which was uneventful. None of the patients were suffering from thrombosis or other vascular diseases. Patients were excluded from the study if they were taking any medications known to affect calcium metabolism (e.g. glucocorticoids, anticonvulsants, calcium or vitamin D supplements, calcitomin (CAL), or bisphosphonates). All of the patients underwent a screening panel, including a complete blood count and serum chemistry profile, and any patients with significant abnormalities in any of these parameters were excluded. Three patients were not included in the study and did not receive oral estrogen treatment because of elevated liver enzymes. Five patients were not included in the study because of prior estrogen treatment due to self medication. At the beginning of the study, all of the patients were eugonadal according to clinical and biochemical criteria. Current exercise, smoking and alcohol consumption were recorded. None of the patients was engaged in excessive exercise activities with a high-impact or high-magnitude bone loading effect (e.g. jumping, sprint running or weight lifting), and none of them had excessive alcohol intake of more than 20 g/day, or excessive smoking of more than 10 pack-age-years. All of the patients continued with their normal diet throughout the study period.
Study design
Retrospective analysis of the study population treated over 24 months with subcutaneous injections of 3.8 mg goserelin acetate (Zoladex GYN; Astra Zeneca, Wedel, Germany) every 4 weeks in combination with 6 mg 17-beta-estradiol-valerate per day (Progynova 21; Schering, Berlin, Germany) until sex-reassignment surgery. Bone mineral density was measured and blood was sampled in the morning before 1000 h to assess serum T, E, and SHBG levels at the beginning of cross-sex hormone treatment, after 12 and 24 months. All blood samples were assayed for hormone parameters immediately in our routine laboratory. In addition, CAL and osteocalcin (OSC) were measured at the beginning of cross-sex hormone treatment, after 12 and 24 months. On the same day, the first morning urine was collected to measure DPD.

Bone mass measurements
BMD of the lumbar spine at the level of L2–L4 and the femoral neck was measured by dual-energy x-ray absorptiometry using a Prodigy densitometer with encore software platform (General Electric Medical Systems, Solingen, Germany). Short-term in vivo reproducibility was 1.04% in the lumbar spine (L2–L4) and 1.7% in the femoral neck, and long-term reproducibility (i.e. the coefficient of variation about the slope of repeated measurements within subjects over 3 years) between 1.9% (lumbar spine (L2–L4)) and 1.8% (femoral neck). BMD is expressed in g/cm² and in age- and race-adjusted values (z-scores) according to the manufactures normative database. Z-scores of 0 to −1.5 are considered normal, from −1.5 to −2.5 as osteopenic, and below −2.5 as osteoporotic.

Biochemical measurements
All assays were performed in our routine diagnostic endocrinology laboratory using established commercial assays routinely monitored by participation in external quality-control programs. Serum parameters (T, E, SHBG, CAL, OSC and DPD) were measured with chemiluminescent enzyme immunoassays (Immulite 2000, Diagnostic Products Corp., Los Angeles, USA). The calibration range of the T assay was 0.7–55 nmol/l, with an analytical sensitivity of 0.5 nmol/l. The cross-reaction with 5alpha-dihydrotestosterone was 2%. The calibration range of the E assay was 73–7342 pmol/l, with an analytical sensitivity of 55 pmol/l. The cross-reactivity with 17-beta-estradiol-valerate was 1.14%. The calibration range of the SHBG assay was up to 180 nmol/l, with an analytical sensitivity of 0.02 nmol/l. No cross-reactivity with other compounds was known. CAL was measured in fasting morning serum samples. After complete clot formation, serum was separated from cells by low-speed centrifugation. The serum was frozen immediately. The calibration range of the assay was up to 2000 pg/ml, with an analytical sensitivity of 2 pg/ml. No cross-reactivity with other compounds was known. DPD was measured in plasma samples. Blood was collected by venipuncture into iced heparinized tubes. After separation of plasma from cells in a refrigerated centrifuge, aliquots were frozen immediately in plastic tubes. The calibration range of the assay was up to 100 pg/ml, with an analytical sensitivity of 6 nM. No cross-reactivity with other compounds, e.g. pyridinoline, was known. To correct for variations in urinary flow, the DPD results were normalized to the urinary creatinine concentration and expressed as nanomoles DPD per liter divided by millimoles creatinine per liter (nMDPD/mM creatinine). Serum and urine samples were stored at −70 °C until assayed.

Statistics
The primary study end point was to show a change in BMD in the femoral neck or lumbar spine due to E treatment in the absence of normal T serum levels in cross-sex hormone-treated transsexuals receiving GnRHa. Changes in the BMD, T, E, SHBG, CAL, OSC and DPD levels after 12 months and 24 months of intervention were compared with baseline levels using paired t tests. The population (n = 40) was strictly treated and the parameters were analyzed according to the protocol (ATP). Statistical analyses were carried out using the SAS program, version 8.1 (SAS Institute, Inc., Cary, NC, USA). Values are expressed as means and s.d. P values less than 0.05 were considered statistically significant.

Results
The baseline characteristics of the complete study population are shown in Table 1. The BMI remained unchanged during the intervention period; the initial BMI was 24.02 (s.d. 4.00) compared with 23.99 (s.d. 3.98) after 12 months and 24.25 kg/m² (s.d. 3.09) after 24 months.

Hormone values
After initiating cross-sex hormone treatment, the patients’ hypogonadal status was regularly checked by measuring gonadotropins every 12 weeks. Adequate suppression of gonadotropins was observed during whole study period (data not shown). There was a significant decrease in serum T levels from 18.65 (s.d. 6.41) to 0.57 (s.d. 0.308; P < 0.001) after 12 months, and to 0.62 nmol/l (s.d. 0.499; P < 0.001)
after 24 months. SHBG levels significantly increased from 50.09 (SD 47.5) to 125 (SD 60.4; P < 0.001) after 12 months, and to 130.05 nmol/l (SD 43.6; P < 0.001) after 24 months. There was also a significant increase of serum E levels from 73.42 (SD 55) to 881.51 (SD 788.51; P < 0.001) after 12 months, and to 923.62 pmol/l (SD 489.66; P < 0.001) after 24 months of cross-sex hormone treatment (Table 2).

### Bone mineral density

Changes in femoral neck BMD and lumbar spine BMD (L2–L4) after 12 months and after 24 months of cross-sex hormone treatment are shown in Fig. 1. In general, an increase in BMD was observed in both the femoral neck and the lumbar spine. The change in the femoral neck BMD after 12 months of treatment, from 1.068 (SD 0.142) to 1.08 g/cm² (SD 0.138) was not considered significant (P = 0.23). However, there was a significant increase (P = 0.010) in the femoral neck BMD from 1.068 (SD 0.142) to 1.109 g/cm² (SD 0.116) after 24 months, while a significant increase in the lumbar spine BMD from 1.200 (SD 0.125) to 1.234 (SD 0.140) after 12 months (P = 0.034), and to 1.274 g/cm² (SD 0.112) after 24 months (P = 0.0001) was observed. The changes in the BMD in the lumbar spine after 24 months compared with the BMD after 12 months were also significant (P = 0.0003). Z-scores of the femoral neck BMD increased from 0.15 (SD 1.02) to 0.20 (SD 1.05) after 12 months and to 0.45 (SD 0.92) after 24 months. Z-scores of the lumbar spine BMD increased from 0.20 (SD 1.32) to 0.25 (SD 1.03) after 12 months and to 0.42 (SD 0.97) after 24 months.

### Bone turnover markers

Data for the bone turnover markers at the beginning of cross-sex hormone treatment, after 12 and 24 months of the intervention period are shown in Table 3. Serum CAL levels of 6.07, 5.95 and 6.32 pg/ml were near the lower reference level, which ranges from 3 to 19 pg/ml in healthy men. OSC values of 11.01, 9.69 and 10.17 ng/ml were also within the normal range of 3.1 to 13.7 ng/ml. The reference range of deoxypyridinoline (DPD) in healthy men has been established as 2.3 – 5.4 nM DPD/mM creatinine. DPD values of 4.27 at the beginning of cross-sex hormone treatment were decreased, although not significantly, to 3.8 after 12 months and were 4.17 nM DPD/mM creatinine after 24 months.

### Discussion

This study demonstrated that high dose E treatment for 24 months is able to increase the BMD in the femoral neck and lumbar spine significantly in men receiving GnRHa for male-to-female cross-sex hormone treatment. Bone resorption was not affected in our study population reflected by unchanged DPD values.

The dosages used were two to three times higher than the recommended doses for hormone replacement therapy (HRT) in postmenopausal women, in whom the physiological decrease in E levels after the menopause is well known to be associated with decreased BMD and an increased risk of osteoporotic fractures. In postmenopausal women there is wide interindividual variability in serum E levels during E treatment for HRT (20). In our study group measured E levels were in the estimated range, accordingly two to three times higher in comparison with women receiving the recommended doses of HRT with 2 mg/day of 17-beta-estradiol-valerate (20, 21).

In different studies E levels were found to correlate better with BMD than T levels (1, 2, 11, 12, 22, 23). However, traditional belief has been that T is the dominant sex steroid regulating bone metabolism in men, whereas previous epidemiological studies have found no association or even a negative association between serum T levels and BMD or vertebral fractures in aging men. Klein et al. (24) and Lorentzon et al. (25) reported data from very young boys without

### Table 1 Baseline characteristics of the study population (n = 40).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Median (IQR)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>38.39 (11.09)</td>
<td>18–62</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.02 (4.00)</td>
<td>18.82–35.51</td>
</tr>
<tr>
<td>Serum T (nmol/l)</td>
<td>18.65 (6.41)</td>
<td>8.00–32.60</td>
</tr>
<tr>
<td>Serum E (pmol/l)</td>
<td>73.16 (16.73)</td>
<td>51.39–172.54</td>
</tr>
<tr>
<td>Serum SHBG (nmol/l)</td>
<td>20.09 (47.50)</td>
<td>125.00–203.05</td>
</tr>
</tbody>
</table>

All values are expressed as means (S.D. and ranges). BMI, body mass index; BMD, bone mineral density; E, estrogen; SHBG, sex hormone-binding globulin; T, testosterone.

### Table 2 Baseline values of serum testosterone (T), estrogen (E), and sex hormone-binding globulin (SHBG) levels in 40 male-to-female transsexuals after 12 months and after 24 months of cross-sex hormone treatment. Data are expressed means (S.D.).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Baseline (n = 40)</th>
<th>12 months (n = 40)</th>
<th>24 months (n = 40)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum T (nmol/l)</td>
<td>18.65 (6.41)</td>
<td>0.57 (0.31)</td>
<td>0.62 (0.50)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum E (pmol/l)</td>
<td>73.40 (55.01)</td>
<td>881.51 (788.51)</td>
<td>923.60 (489.71)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum SHBG (nmol/l)</td>
<td>50.09 (47.50)</td>
<td>125.00 (60.40)</td>
<td>130.05 (43.60)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

E, normal ranges < 206 pmol/l; SHBG, 13–71 nmol/l; T, 8.49–55.47 nmol/l. Inter- and intra-assay CV’s were always below 11% at mid-range concentrations.
Bone turnover markers after 12 months and 24 months of cross-sex hormone treatment. Data are expressed as means ± S.D.

<table>
<thead>
<tr>
<th></th>
<th>Baseline (n = 40)</th>
<th>12 months (n = 40)</th>
<th>24 months (n = 40)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcitonin (pg/ml)</td>
<td>6.07 (3.98)</td>
<td>5.95 (4.28)</td>
<td>6.32 (5.14)</td>
<td>n.s.</td>
</tr>
<tr>
<td>Osteocalcin (ng/ml)</td>
<td>11.01 (4.21)</td>
<td>9.69 (4.36)</td>
<td>10.17 (4.78)</td>
<td>n.s.</td>
</tr>
<tr>
<td>Deoxypyridinoline (DPD) (nM DPD/nM creatinine)</td>
<td>4.27 (1.51)</td>
<td>3.80 (1.17)</td>
<td>4.17 (1.17)</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

n.s., not significant; calcitonin, normal ranges <18.20 pg/ml; Osteocalcin, 3.10–13.70 ng/ml; DPD, 2.30–5.40 nM DPD/nM creatinine. Inter- and intra-assay CV’s were always below 11% at mid-range concentrations.
GnRHa application in the presence of concomitant high dose E treatment.

Bone resorption remained unchanged in our study population, but increased BMD may be due to either stimulated bone formation or increased bone mineralization. It also remains unclear, whether the BMD increasing effect is due to the high dosage of Es or due to the kind of E. In contrast, van Kesteren et al. used ethinyl estradiol 100 μg/day in their study populations and the dosage was reduced to 50 μg/day after SRS (18, 27). Different studies have described no effect on BMD of the administration of ethinyl estradiol for contraception or in young women suffering from amenorrhea, while bone turnover markers were decreased (41–45). In postmenopausal women, ethinyl estradiol plus calcium administration for 2 years increased BMD in the lumbar spine, as reported by Speroff et al. in 1996 (46). Doren et al. (47) reviewed the effect of specific postmenopausal hormone therapies on bone mineral density in women published between 1990 and December 2002. The impact on BMD did not appear to differ between any E groups.

We used 17-beta-estradiol-valerate in our E treatment regimen, which is more effective in generating a greater hormonal reservoir of estrogenic metabolites—for example, estrone, estrone sulfate, estradiol, and estradiol sulphate—and their metabolism is equivalent to that of natural 17-beta-estradiol (21). Also taking into account that this study, due to its very special patient group, has some limitations relating to the study design (e.g., missing control group, retrospective analysis per protocol), it may be speculated, that the use of 17-beta-estradiol together with the higher E dosages might be the cause for the BMD increasing effect in the study group.

In summary, E treatment using 17-beta-estradiol-valerate at dosages of 6 mg/day increased BMD significantly in the femoral neck and lumbar spine in men receiving GnRHa, who are at increased risk of developing osteoporosis. There is no risk of developing osteoporosis in male-to-female transsexuals receiving GnRHa when there is an adequate E substitution.

References


45 Reed SD, Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE & Ott SM. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception 2003 68 177–182.

46 Speroff L, Yakovlev I, Jaffe RB, Judd HL & Wynn J. Estrogen increases BMD in M–F transsexuals

113EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005) 151

Estrogen increases BMD in M–F transsexuals

113

Downloaded from Bioscientifica.com at 06/17/2022 04:25:38AM via free access